First Trust Advisors LP Enanta Pharmaceuticals Inc Transaction History

First Trust Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 02, 2021	SELL	$41.16 - $47.47 $275,895 - $318,191	-6,703 Closed	0 $0
Q3 2020 Nov 05, 2020	BUY	$43.36 - $53.53 $78,568 - $96,996	1,812 Added 37.05%	6,703 $307,000
Q2 2020 Jul 22, 2020	BUY	$46.37 - $57.58 $226,795 - $281,623	4,891 New	4,891 $246,000
Q4 2019 Feb 03, 2020	SELL	$57.95 - $66.61 $509,786 - $585,968	-8,797 Closed	0 $0
Q3 2019 Nov 04, 2019	SELL	$60.08 - $88.17 $1.97 Million - $2.9 Million	-32,838 Reduced 78.87%	8,797 $529,000
Q2 2019 Jul 30, 2019	BUY	$81.3 - $97.35 $1.33 Million - $1.6 Million	16,401 Added 65.0%	41,635 $3.51 Million
Q1 2019 May 09, 2019	BUY	$69.08 - $105.66 $185,203 - $283,274	2,681 Added 11.89%	25,234 $2.41 Million
Q4 2018 Feb 07, 2019	SELL	$65.41 - $84.65 $1.62 Million - $2.1 Million	-24,766 Reduced 52.34%	22,553 $1.6 Million
Q3 2018 Oct 25, 2018	SELL	$85.46 - $126.37 $1.88 Million - $2.77 Million	-21,957 Reduced 31.69%	47,319 $4.04 Million
Q2 2018 Aug 02, 2018	BUY	$81.85 - $120.51 $5.67 Million - $8.35 Million	69,276 New	69,276 $8.03 Million

110

21.1M

4.8K

4.6K

Ticker ENTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,724,900
Market Cap $183M
Description
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and li...

Get notified when there are updates to the investment portfolio of First Trust Advisors LP, based on Form 13F filings with the SEC.

Stay updated on First Trust Advisors LP with notifications on news.